With the completion of our recent IPO, we have substantial capital to ... as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...

Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

Cash, cash equivalents and marketable securities were $352.4 million as of December 31, 2024, compared to $75.2 million as of December 31, ...

Recent Business Highlights Completed initial public offering (IPO) In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...

With the completion of our recent IPO, we have substantial capital to continue this momentum, enabled by our highly experienced team and committed partners. We expect 2025 to be another year of ...

Metsera cleared that benchmark Monday, with a jump from 78 to 82 Monday. Please watch the video at Investors.com - How To Find The Best IPO Stocks IBD's unique rating identifies market leadership with ...

Despite several big deals that buoyed the numbers, North America early- and seed-stage investment declined to multiquarter lows in Q1, and reported round counts fell across stages.